Molecular mechanism of Afadin substrate recruitment to the receptor phosphatase PTPRK via its pseudophosphatase domain

  1. Iain M Hay
  2. Katie E Mulholland
  3. Tiffany Lai
  4. Stephen C Graham
  5. Hayley J Sharpe  Is a corresponding author
  6. Janet E Deane  Is a corresponding author
  1. Cambridge Institute for Medical Research, University of Cambridge, United Kingdom
  2. Signalling Programme, Babraham Institute, United Kingdom
  3. Department of Pathology, University of Cambridge, United Kingdom
5 figures, 1 table and 1 additional file

Figures

Figure 1 with 3 supplements
PTPRK interacts directly with the Afadin C-terminal coiled-coil (CC) region.

(A) Top: schematic of full-length human Afadin, with domain annotation based on UniProt ID P55196, showing Ras-association (RAS, yellow), CC (green), forkhead-associated (FHA, orange), dilute (DIL, blue), PDZ (pink), F-actin binding (magenta) domains, and LGN-binding peptide motif (black). The putative PTPRK target site Y1230 is also highlighted (red). Bottom: predicted local distance difference test (pLDDT) for the Afadin AlphaFold2 (AF2) prediction from the AlphaFold Protein Structure Database (P55196, retrieved 7/2/2022). A pLDDT score <50 is predictive of protein disorder (Jumper et al., 2021). (B) Immunoblot analysis of pervanadate-treated MCF10A cell lysates incubated for 45 min at 4°C with 0.3 µM of the indicated recombinant PTP domains. Note: the total Afadin antibody is sensitive to phosphorylation likely at Y1230 (antigen: Afadin 1091–1233) and therefore indicates dephosphorylated Afadin. A full time course is quantified in Figure 1—figure supplement 2E. (C) Immunoblot analysis of streptavidin bead-conjugated PTPRK-ICD pull-downs from wheat germ lysate containing full-length Afadin. (D) Top: schematic of different Afadin C-terminal truncations used in initial mapping experiments, colored as in (A). Bottom: immunoblot analysis of streptavidin bead-conjugated PTPRK-ICD pull-downs from wheat germ lysates containing C-terminal Afadin truncations. Prey proteins enriched on both beads-only and PTPRK pull-downs were considered to be nonspecific interactions. (E) Top: schematic of different Afadin C-terminal GST-fusion constructs used for interaction mapping. Bottom: pull-downs using streptavidin bead-conjugated PTPRK-ICD with purified GST-Afadin fusion proteins, followed by SDS-PAGE and Coomassie staining. (F) Top: sequence of Afadin-CC showing predicted helical region (green block) as observed in the full-length Afadin AF2 prediction. This region contains a high number of charged residues, which have been highlighted (basic, blue; acidic, red). Bottom: pull-downs using streptavidin-conjugated-PTPRK-ICDs with either GST or GST-Afadin-CC in the presence of increasing NaCl concentrations (10, 100, 250, 500 mM; left to right) followed by SDS-PAGE and Coomassie staining. Gels and blots shown in this figure are representative of n 3 independent experiments.

Figure 1—figure supplement 1
Disorder predictions for Afadin.

Top: schematic of full-length human Afadin (also known as AF6 or MLLT4), with domain annotation based on UniProt ID P55196, colored as in main Figure 1A. The predicted local distance difference test (pLDDT) for the Afadin AlphaFold2 (AF2) prediction from the AF Protein Structure Database (ID: P55196, retrieved 7/2/2022) is aligned to disorder predictions from the PONDR and IUPred3 servers, highlighting the agreement of pLDDT scores with dedicated disorder prediction methods. For clarity, the Y axis for the AF2 pLDDT plot has been inverted, so as to have predicted disorder consistently displayed in the top half of all graphs.

Figure 1—figure supplement 2
Afadin-pY1230 antibody validation.

(A) Top: phosphopeptide antigen used to generate a sheep polyclonal anti-Afadin-pY1230 antibody (tthis study). Middle: amino acid numbers of epitope used to generate a mouse monoclonal against Afadin (BD Transduction Laboratories). Note that the epitope encompasses Y1230. Bottom: approximate peptide used to generate rabbit monoclonal antibody against Afadin. Note that there is no overlap with Y1230. Numbering based on UniProt: P55196-4. (B) Lysates from confluent wildtype and PTPRK KO MCF10As were analyzed by immunoblot. (C) Replicate immunoblot analyses of MCF10A cells either untransfected (UT) or transfected with non-targeting control (NTC) and AFDN (Afadin)-targeting small interfering (si)RNAs. Tyrosine phosphorylation of cellular proteins was stimulated by treatment with 100 μM pervanadate (PV) for 30 min prior to cell lysis. Note that the anti-Afadin antibody (BD) is sensitive to tyrosine phosphorylation. (D) HEK293T cells were transfected with indicated mScarlet plasmids and treated with or without 100 μM PV. Following cell lysis, indicated samples were dephosphorylated with calf intestinal phosphatase (CIP). Lysates were then analyzed by SDS-PAGE and immunoblotting. MScarlet-Afadin and endogenous Afadin can be resolved, as indicated, using an 8% polyacrylamide gel. Note: there are multiple bands detected by Afadin pY1230. This could reflect on target detection of Afadin isoforms or off-target detection of proteins with similar peptide sequences. However, since it is clear which band is the full-length longest isoform of Afadin we have not sought their identity for this study. (E) Densitometric quantification of immunoblots in Figure 1B (45 min time point shown). Top: Afadin-pY1230 time points normalized to no protein control. Bottom: paxillin-pY118 time points normalized to no protein control. (F) Wildtype or PTPRK KO MCF10As, with stably integrated doxycycline-inducible tGFP, PTPRK, or PTPRK-C1089S, were cultured for 6 days with indicated concentrations of doxycycline supplemented for the final 48 hr, then lysed and subjected to immunoblot analysis. (G) Densitometric quantification of immunoblots from panel (F). Afadin-pY1230 signal is normalized to the total Afadin from the same experiment after reprobing the membrane, comparing 0 ng/ml and 500 ng/ml doxycycline (Dox) samples. Top: quantification of panel (F). Bottom: quantification of biological replicate experiment.

Figure 1—figure supplement 3
Purification of in vivo biotinylated PTP domains.

(A) Left: following Ni-NTA affinity chromatography, in vivo biotinylated PTPRK D1 and D2 domains were purified by size-exclusion chromatography (SEC) on an S75 16/600 column. Right: after SEC purification, in vivo biotinylated PTPRK D1 and D2 domains were incubated with or without streptavidin, resolved by SDS-PAGE and visualized by Coomassie staining. The mobility shift upon streptavidin binding to biotinylated protein is indicated by a red arrowhead. (B) Left: following Ni-NTA affinity chromatography, in vivo biotinylated PTPRK-ICD was purified by SEC on anS200 16/600 column. Right: after SEC purification, biotinylation of PTPRK-ICD was assessed as described in (A).

Figure 2 with 1 supplement
PTPRK:Afadin-CC forms an equimolar complex with micromolar affinity.

(A) Size-exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) analysis of Afadin-CC. The SEC elution profile (normalized differential refractive index [dRI]; thin red line) and weight-averaged molecular mass (red thick line) are shown. The dashed horizontal line indicates the predicted mass of monomeric Afadin-CC after removal of the GST affinity tag. (B) Isothermal titration calorimetry (ITC) titration curves of the interaction between Afadin-CC and PTPRK-ICD. Left: baseline-corrected differential power (DP) plotted over time. Right: normalized binding curve showing the integrated change in enthalpy against the molar ratio. (C) PTPRK pull-downs using streptavidin bead-conjugated ICD, D1 or D2 domains against GST-Afadin-CC followed by SDS-PAGE and Coomassie staining. Gel is representative of n 3 independent experiments. (D) ITC titration curves of the interaction between Afadin-CC and PTPRK-D2. Data presented as described for (B). (E) Table showing the dissociation constant (KD), enthalpy (ΔH), and number of binding sites (N) for the ITC experiments performed in this study. Data represents the mean ± SEM of n = 2 independent experiments.

Figure 2—figure supplement 1
GST-tag removal from Afadin-CC for size-exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) and isothermal titration calorimetry (ITC) experiments.

(A) GST was removed from GST-Afadin-CC by overnight cleavage with GST-3C protease. Cleaved GST and GST-3C were removed by incubation with GSH-sepharose 4B (GSH-resin). (B) Residual cleaved GST was removed by SEC of the Afadin-CC sample on an S75 16/600 column.

Figure 3 with 3 supplements
Structural prediction of the PTPRK-D2:Afadin-CC complex.

(A) Top: schematic of different GST-Afadin-CC truncations used for further interaction mapping experiments. Regions within the predicted helix are marked by a green bar. Dashed lines indicate deleted regions in N-terminal truncations. Bottom: pull-downs using streptavidin bead-conjugated PTPRK-ICD against GST-Afadin-CC truncations followed by SDS-PAGE and Coomassie staining. (B) The top model generated by AF2-Multimer of the PTPRK-D2 domain (blue) in complex with Afadin-CC (green). (C) Prediction quality analysis for the top PTPRK-D2:Afadin-CC complex model. Top: plot of predicted local distance difference test (pLDDT) for Afadin-CC (green) and PTPRK-D2 (blue). Bottom: predicted aligned error (PAE) plot for the PTPRK-D2:Afadin-CC complex. Quality analyses for all five generated models are available in Figure 3—figure supplement 3. (D) PTPRK pull-downs using streptavidin bead-conjugated PTPRK-ICD against GST-Afadin-CC point mutants followed by SDS-PAGE and Coomassie staining. Residue numbering of the Afadin-CC sequence is shown below. Residues that were mutated are in bold underline, with mutations that alter Afadin-CC binding highlighted in yellow. (E) Molecular surface representation of PTPRK-D2 (blue) in complex with Afadin-CC (green ribbons). The sidechains of Afadin-CC residues that were mutated in (D) are shown in stick representation, with residues that were shown to be critical for PTPRK binding highlighted in yellow. Gels shown in this figure are representative of n 3 independent experiments.

Figure 3—figure supplement 1
Structural prediction of the PTPRK-D2:Afadin-CC complex.

(A) Ribbon diagram of the AF2-Multimer prediction for the PTPRK-D2 domain (blue) in complex with the full Afadin-CC (aa. 1393–1455, green). Afadin-CC residues that contribute to the interaction interface are highlighted in orange. (B) Graph of buried surface area (Å2) per residue of Afadin-CC for the PTPRK-D2:Afadin-CC complex. All residues that contribute to the interface are within the core sequence of charged residues (highlighted red/blue for acidic/basic, respectively) within the helical region of Afadin-CC (highlighted by green cylinder). Buried surface area calculations were performed using the ‘Protein interfaces, surfaces and assemblies’ service (PISA) at the European Bioinformatics Institute (Krissinel and Henrick, 2007).

Figure 3—figure supplement 2
Species conservation of Afadin-CC.

Multiple-sequence alignment of the equivalent Afadin-CC region (hsAFDN aa. 1393–1455) from human (Homo sapiens), mouse (Mus musculus), dog (Canis familiaris), frog (Xenopus laevis), zebrafish (Danio rerio), and fruit fly (Drosophila melanogaster).

Figure 3—figure supplement 3
Prediction quality analysis of AF2 multimer-generated PTPRK-D2:Afadin-CC complex models.

(A) The five AF2-Multimer-generated PTPRK-D2:Afadin-CC models were superposed using the PTPRK-D2 chain only. The Afadin-CC chains of each ranked model are shown as cylinders (colored as indicated) with N- and C-termini highlighted. (B) Plot of predicted local distance difference test (pLDDT) for the Afadin-CC chain of each ranked PTPRK-D2:Afadin-CC model, colored as in (A). (C, D) Predicted aligned error (PAE) plot for highest (C, model 1) and lowest (D, model 5) ranked models for the PTPRK-D2:Afadin-CC complex. The high expected position error for Afadin-CC vs. PTPRK-D2 residues in model 5 indicates a low confidence in the relative positioning of these domains for the lower-ranked models versus that observed for model 1.

Figure 4 with 4 supplements
PTPRK binds Afadin-CC via an acidic pocket distal from the D2 ‘active’ site.

(A) Conservation mapping of the PTPRK-D2:Afadin-CC interface. PTPRK-D2 is shown (blue surface representation) in complex with Afadin-CC (green ribbons). Residues that are conserved in both PTPRK/PTPRU but not PTPRM are potentially involved in Afadin binding specificity and are highlighted on the PTPRK-D2 surface in red. Cα atoms of Afadin-CC residues identified as critical for PTPRK binding (see Figure 3D and E) are highlighted by yellow spheres. For clarity and orientation, the D1 domain of PTPRK has been modeled in transparent surface representation (white) and both D1 and D2 ‘active’ sites highlighted in purple and dotted circles. Three orientations rotated by 90° are shown. (B) Inset shows the molecular detail of key residues at the highlighted region on the PTPRK-D2 surface. Equivalent residues for the highlighted region are shown for PTPRK (blue) and PTPRM (wheat) in stick representation. (C) Electrostatic properties of PTPRK (left) and PTPRM (right) D2 domains, colored by electrostatic potential (–5 to +5 kT, as red and blue, respectively). Domains are oriented as shown in (B). The key PTPRM substitutions highlighted in (B) result in altered surface topology and electrostatic potentials compared to PTPRK. (D) Pull-downs using streptavidin bead-conjugated WT, G1273H, or L1335R PTPRK-D2 domains against GST-Afadin-CC followed by SDS-PAGE and Coomassie staining. (E) Pull-downs using streptavidin bead-conjugated WT and G1273H/L1335R double mutant (DM) PTPRK-ICD and D2 domains against GST-Afadin-CC followed by SDS-PAGE and Coomassie staining. (F) Isothermal titration calorimetry (ITC) data showing a lack of interaction between Afadin-CC and PTPRK-D2 DM. Left: baseline-corrected differential power (DP) plotted over time. Right: normalized binding curve showing the integrated change in enthalpy against the molar ratio. To highlight lack of binding, DM data (black) is shown superimposed onto the data for the WT D2 domain (gray), which is also shown in Figure 2D. (G) Immunoblot analysis of streptavidin bead-conjugated PTPRK pull-downs from wheat germ lysate containing full-length Afadin. Both WT and DM PTPRK-ICD and D2 domains were assayed for their ability to bind full-length Afadin. (H) GST pull-downs using GST-Afadin-CC against PTPRK-ICD and D2 WT, DM, F1225A, and M-loop, followed by SDS-PAGE and Coomassie staining. Gels and blots shown in this figure are representative of n 3 independent experiments.

Figure 4—figure supplement 1
Mapping of unique PTPRM residues.

Multiple-sequence alignment of human PTPRK, PTPRU, and PTPRM D2 domain sequences. Residues that are conserved in both PTPRK and PTPRU, but differ in PTPRM, which were used for interaction site mapping, are highlighted in red. Asterisks denote divergent PTPRM residues present at the PTPRK-D2:Afadin-CC interface, as illustrated in Figure 3D and E.

Figure 4—figure supplement 2
Localization of additional PTPRK D2 mutations.

(A) Ribbon diagram of PTPRK-D2 (blue) and PTPRM-D2 (wheat) in complex with Afadin-CC (green). PTPRK-F1225 stacks with hydrophobic W1418-Y1419 residues of Afadin-CC and this residue is conserved in PTPRM. (B) Sequence alignment of an acidic loop in PTPRK (aa. 1369–1378) with corresponding PTPRM sequence, colored by % identity. The M-loop mutant of PTPRK used in Figure 4H has been mutated to the PTPRM sequence indicated here. This acidic loop in both PTPRK (blue) and PTPRM (wheat) is located adjacent to the Afadin-CC (green) binding interface.

Figure 4—figure supplement 3
Thermal stability of PTPRK-D2 mutants.

Differential scanning fluorimetry of PTPRK-D2 WT (black), F1255A (red), M-loop (blue), and double mutant (DM, yellow) recombinant proteins. Curves and melting temperature (Tm) values shown represent the mean ± SD of n = 4 technical replicates.

Figure 4—figure supplement 4
Prediction quality of models prior to biochemical mapping.

(A) The 5 AF2-Multimer generated PTPRK-ICD:Afadin-CC models were superposed using the PTPRK-ICD chain only. The Afadin-CC chains of each ranked model are shown as cylinders (colored as indicated). (B) Plot of predicted local distance difference test (pLDDT) for the Afadin-CC chain of each ranked PTPRK-ICD:Afadin-CC model, colored as in (A). These scores are markedly lower than that for the model generated using the PTPRK-D2 (see Figure 3—figure supplement 2). (C–, D) Predicted aligned error (PAE) plot for highest (C, model 1) and lowest (D, model 5) ranked models for the PTPRK-D2:Afadin-CC complex. Both top- and bottom-ranked models generated using the PTPRK-ICD have worse PAE scores when compared to the PTPRK-D2 models (see Figure 3—figure supplement 2).

Figure 5 with 1 supplement
Mutation of residues at the interaction interface inhibit dephosphorylation of Afadin by PTPRK.

(A) Time course of pNPP dephosphorylation by WT (black) and double mutant (DM, red) PTPRK-ICD. Error bars represent ± SEM of n = 2 independent experiments. (B) Immunoblot analysis of pervanadate-treated MCF10A lysates incubated for 1.5 hr at 4°C with 0.3 µM of PTPRK-ICD WT or DM. (C) Immunoblot analysis of pervanadate-treated MCF10A lysates incubated for 1.5 hr at 4°C with 0.3 µM of PTPRK-ICD WT or DM followed by pTyr immunoprecipitation (IP). Dephosphorylated proteins are depleted from pTyr-IPs and/or enriched in supernatants (sup.). Gels and blots shown in this figure are representative of n 3 independent experiments.

Figure 5—figure supplement 1
PTPRK-ICD-DM displays impaired dephosphorylation of Afadin-pY1230, but not p120Cat-pY228.

Densitometric quantification of immunoblots in Figure 5B (90 min time point shown) at indicated time points. Top: Afadin-pY1230 normalized against no protein control. Middle: p120Cat-pY228 normalized against no protein control. Bottom: paxillin-pY118 normalized against no protein control. Error bars represent mean ± SD, n = 2.

Tables

Appendix 1—key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Gene (human)PTPRKENSEMBL: ENSG00000152894
Gene (human)AFDNENSEMBL: ENSG00000130396
Cell line (human)MCF10AATCCCRL-10317
Cell line (human)HEK293TD. RonN/A
Transfected
construct (human)
MCF10A PTPRK
KO pooled.tGFP
Fearnley et al., 2019N/ALentivirally transduced stable cell line
Transfected
construct (human)
MCF10A PTPRK KO pooled.tGFP.
P2A.PTPRK
Fearnley et al., 2019N/ALentivirally transduced stable cell line
Transfected
construct (human)
MCF10A PTPRK KO
pooled.tGFP.P2A.
PTPRK.C1089S
Fearnley et al., 2019N/ALentivirally transduced stable cell line
Transfected
construct (human)
MCF10A tGFPFearnley et al., 2019N/ALentivirally transduced stable cell line
AntibodyAnti-PTPRK
(rabbit monoclonal)
Fearnley et al., 20192.H4Western blot: 1:1000
AntibodyAnti-Afadin-pY1230
(sheep polyclonal)
This studyN/ACharacterized in Figure 1—figure supplement 2
Western blot: 1 µg/ml
(with 10 µg/ml
non-phosphopeptide)
Available on request from Sharpe lab, Babraham Institute
AntibodyAnti-Afadin
(mouse monoclonal)
BD Transduction LaboratoriesCat#610732Western blot: 1:1000
AntibodyAnti-p120 catenin
(mouse monoclonal)
BD Transduction LaboratoriesCat#610133Western blot: 1:1000
AntibodyAnti-RFP
(mouse monoclonal)
Thermo Fisher ScientificCat#MA5-15257Western blot: 1:1000
AntibodyAnti-Turbo-GFP
(mouse monoclonal)
OriGeneTA150041Western blot: 1:1000
AntibodyAnti-Afadin
(rabbit monoclonal)
Cell Signaling TechnologyCat#13531Western blot: 1:1000
AntibodyAnti-His (mouse
monoclonal)
Cell Signaling TechnologyCat#2366Western blot: 1:1000
AntibodyAnti-phospho-tyrosine
(P-Tyr-1000) (rabbit
monoclonal)
Cell Signaling TechnologyCat#8954Western blot: 1:2000
AntibodyAnti-paxillin (rabbit monoclonal)Cell Signaling TechnologyCat#12065 (D9G12)Western blot: 1:1000
AntibodyAnti-phospho-p120
catenin (Y904)
(rabbit polyclonal)
Cell Signaling TechnologyCat#2910Western blot: 1:1000
AntibodyAnti-phospho-p120
catenin (Y228)
(rabbit polyclonal)
Cell Signaling TechnologyCat#2911Western blot: 1:1000
AntibodyAnti-phospho-
paxillin (Y118)
Cell Signaling TechnologyCat#2541Western blot: 1:1000
AntibodyAnti-Tubulin (alpha)
(mouse monoclonal)
SigmaCat#T6199Western blot: 1:1000
AntibodyHRP-conjugated-
donkey anti-goat IgG
Jackson ImmunoResearchCat#705-035-147Western blot: 1:5000
AntibodyHRP-conjugated-
donkey anti-rabbit IgG
Jackson ImmunoResearchCat#711-035-152Western blot: 1:5000
AntibodyHRP-conjugated-
donkey anti-mouse IgG
Jackson ImmunoResearchCat#711-035-152Western blot: 1:5000
AntibodyHRP-conjugated-mouse anti-
rabbit IgG (conformation specific)
Cell Signaling TechnologyCat#5127SWestern blot: 1:2000
Recombinant
DNA reagent
pET15bJ. DeaneN/A
Recombinant
DNA reagent
pET15b.His.TEV.AviFearnley et al., 2019N/A
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.ICD
Fearnley et al., 2019UniProt: Q15262-3
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.ICD.D1057A
Fearnley et al., 2019UniProt: Q15262-3
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.ICD.C1089S
Fearnley et al., 2019UniProt: Q15262-3
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.D1
Fearnley et al., 2019UniProt: Q15262-3
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.D2
Fearnley et al., 2019UniProt: Q15262-3
Recombinant
DNA reagent
PET15b.His.TEV.Avi.
PTPRK.D2.G1273H
This studyUniProt: Q15262-3Mutations: G1273H
See Figure 4
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.D2.L1335R
This studyUniProt: Q15262-3Mutations: L1335R

See Figure 4D
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.ICD.DM
This studyUniProt: Q15262-3Mutations: G1273H L1335R
See Figure 4E
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.D2.DM
This studyUniProt: Q15262-3Mutations: G1273H L1335R
See Figure 4E
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.D2.F1225A
This studyUniProt: Q15262-3Mutation: F1225A
See Figure 4H
Recombinant
DNA reagent
pET15b.His.TEV.Avi.
PTPRK.D2.M-loop
This studyUniProt: Q15262-3Mutations: C1372Y E1373N
E1374G
See Figure 4H
Recombinant
DNA reagent
pGEX-6P-1J. DeaneN/A
Recombinant
DNA reagent
pGEX-6P-Afadin-1098-C*This studyUniProt: P55196-4See Figure 1E
Recombinant
DNA reagent
pGEX-6P-Afadin-1098-1507This studyUniProt: P55196-4See Figure 1E
Recombinant
DNA reagent
pGEX-6P-Afadin-1098-1407This studyUniProt: P55196-4See Figure 1
Recombinant DNA reagentpGEX-6P-Afadin-1514-C*This studyUniProt: P55196-4See Figure 1E
Recombinant DNA reagentpGEX-6P-Afadin-1393-C*This studyUniProt: P55196-4See Figure 1E
Recombinant DNA reagentpGEX-6P-Afadin-1393-1507This studyUniProt: P55196-4See Figure 1E
Recombinant DNA reagentpGEX-6P-Afadin-CCThis studyUniProt: P55196-4Encoding amino acids: 1393–1455

See Figure 1F
Recombinant DNA reagentpGEX-6P-Afadin-CC-WY>AAThis studyUniProt: P55196-4Mutations: W1418A Y1419A
See Figure 3D
Recombinant DNA reagentpGEX-6P-Afadin-CC-ER>AAThis studyUniProt: P55196-4Mutations: E1429A R1430A
See Figure 3D
Recombinant DNA reagentpGEX-6P-Afadin-CC-RK>AAThis studyUniProt: P55196-4Mutations: R1432A K1433A
See Figure 3D
Recombinant DNA reagentpGEX-6P-Afadin-CC-Q>AThis studyUniProt: P55196-4Mutations: Q1443A
See Figure 3D
Recombinant DNA reagentpGEX-6P-Afadin-CC-T>AThis studyUniProt: P55196-4Mutations: T1446A
See Figure 3D
Recombinant DNA reagentpGEX-6P-Afadin-CC-QT>AAThis studyUniProt: P55196-4Mutations: Q1443A T1446A
See Figure 3D
Recombinant DNA reagentpmScarlet-C1Z. KadlecovaN/A
Recombinant DNA reagentpmScarlet-AfadinThis studyUniProt: P55196-4See Figure 1—figure supplement 2D
Recombinant DNA reagentpmScarlet-Afadin-Y1226FThis studyUniProt: P55196-4Mutation: Y1226F
See Figure 1—figure supplement 2D
Recombinant DNA reagentpmScarlet-Afadin-Y1230FThis studyUniProt: P55196-4Mutation: Y1230F
See Figure 1—figure supplement 2D
Recombinant DNA reagentpmScarlet-Afadin-YF YFThis studyUniProt: P55196-4Mutations: Y1226F Y1230F
See Figure 1—figure supplement 2D
Sequence-based reagentON-TARGETplus
Human AFDN siRNA:
Dharmacon, GE HealthcareL-020075-02-0005
Sequence-based reagentON-TARGETplus
Non-targeting pool siRNA:
Dharmacon, GE HealthcareCat#D-001810-10-05
Peptide, recombinant proteinCatalaseSigmaCat#C134514
Peptide, recombinant proteinCholera toxinSigmaCat#C-8052
Peptide, recombinant proteinInsulinSigmaCat#I-1882
Peptide, recombinant proteinEpidermal growth factorPeproTechCat#AF-100-15-1MG
Commercial assay or kitQ5 High-Fidelity
DNA Polymerase
New England BiolabsCat#M0491S
Commercial assay or kitPhusion Hot Start II
DNA polymerase
Thermo Fisher ScientificCat#F549L
Commercial assay or kitEZ-ECL substrateGeneflowCat#K1-0170
Commercial assay or kitInstantBlueExpedeonCat#ISB1L
Commercial assay or kitPhosphatase inhibitor cocktailRocheCat#04906845001
Commercial assay or kitTaqMan Universal Master Mix IIApplied BiosystemsCat#4440040
Chemical compound, drugHydrogen peroxideThermo Fisher ScientificCat#H/1750/15
Chemical compound, drugSodium orthovanadateAlfa AesarCat#J60191
Chemical compound, drug250 kDa-FITC-dextranSigmaCat#FD250S-100MG
Chemical compound, drugPara-Nitrophenol-
phosphate (pNPP)
New England BiolabsCat#P0757
Chemical compound, drugIPTGGeneronCat#GEN-S-02122
Chemical compound, drugD-biotinSigmaCat#B4639
Chemical compound, drugl-GlutamineSigmaCat#G7513
Chemical compound, drugHydrocortisoneSigmaCat#H-0888
Chemical compound, drugNH4OHAcros OrganicsCat#460801000
Chemical compound, drugMethanol-free 16%
(w/v) paraformaldehyde (PFA)
Thermo Fisher ScientificCat#28906
Software, algorithmFIJI/ImageJLaboratory for Optical and
Computational Instrumentation
University of Wisconsin-Madison
Software, algorithmGraphPadPrism
Software, algorithmChimeraUCSF
Strain, strain
background
(Escherichia coli)
STABLE competent E. coliNEBCat#C3040I
Strain, strain
background (E. coli)
DH5alpha competent E. coliInvitrogenCat#18265017
Strain, strain
background (E. coli)
BL21 DE3
Rosetta E. coli
J. DeaneN/A
OtherDMEMThermo Fisher ScientificCat#41965-039Component of cell culture media
OtherHam's F-12SigmaCat#N4888Component of cell culture media
OtherHorse serumThermo Fisher ScientificCat#16050-122Component of cell culture media
OtherHRP-conjugated streptavidinThermo Fisher ScientificCat#434323For detection of biotinylated proteins
OtherFetal bovine serumSigmaCat#F7524-500mlComponent of cell culture media
OtherTrypsin-EDTA solutionSigmaCat#T3924Reagent used to lift cells
from culture vessel
OtherGeneJuiceMerck MilliporeCat#70967-3Transfection reagent
OtherEDTA-free protease inhibitorsRocheCat#11836170001Component of cell lysis buffer
OtherLipofectamine
RNAiMAX
InvitrogenCat#13778075Transfection reagent
OtherOptiMEMThermo Fisher ScientificCat#31985070Component of cell culture media
OtherProtein G agarose
beads
Merck MilliporeCat#16-266Affinity reagent for
immunoprecipitations
OtherNi-NTA agaroseQIAGENCat#1018244Affinity reagent for His-tag purification
OtherStreptavidin-coated
magnetic beads
New England BiolabsCat#S1420SAffinity reagent for Avi-tag pull-downs
OtherStreptavidin agaroseThermo Fisher ScientificCat#20357Affinity reagent for Avi-tag pull-downs
OtherSuperdex 200 16/600 columnGE HealthcareCat#28-9893-35Chromatography column
OtherSuperdex 75 16/600 columnGE HealthcareCat#28-9893-33Chromatography column
OtherUltracel-3K regenerated
cellulose centrifugal filter
Merck MilliporeCat#UFC900324Chromatography column
OtherUltracel-10K regenerated
cellulose centrifugal filter
Merck MilliporeCat#UFC901024Used for protein concentration
OtherUltracel-30K regenerated
cellulose centrifugal filter
Merck MilliporeCat#UFC903024Used for protein concentration
OtherNuPAGE 4–12% Bis-Tris gelThermo Fisher ScientificCat#NP0321BOXSDS PAGE electrophoresis gel
OtherSlide-A-Lyzer 20K MWCOThermo Fisher ScientificCat#66003Dialysis cassette
OtherSYPRO Orange dyeThermo Fisher ScientificCat#S6650Used for thermal shift assays
OtherMycoAlert PLUS
Mycoplasma Detection Kit
Lonza#LT07-705Used for testing cell lines
OtherMycoProbe Mycoplasma
Detection Kit
R&D Systems#CUL001BUsed for testing cell lines

Additional files

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Iain M Hay
  2. Katie E Mulholland
  3. Tiffany Lai
  4. Stephen C Graham
  5. Hayley J Sharpe
  6. Janet E Deane
(2022)
Molecular mechanism of Afadin substrate recruitment to the receptor phosphatase PTPRK via its pseudophosphatase domain
eLife 11:e79855.
https://doi.org/10.7554/eLife.79855